Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash & Current Investments (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Cash & Current Investments readings, the most recent being $1.5 billion for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 37.57% to $1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 billion, a 37.57% increase, with the full-year FY2025 number at $1.5 billion, up 37.57% from a year prior.
  • Cash & Current Investments hit $1.5 billion in Q4 2025 for Neurocrine Biosciences, up from $1.1 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $1.5 billion in Q4 2025 to a low of $648.3 million in Q2 2022.
  • Median Cash & Current Investments over the past 5 years was $976.2 million (2023), compared with a mean of $971.1 million.
  • Biggest five-year swings in Cash & Current Investments: dropped 26.74% in 2022 and later skyrocketed 50.66% in 2023.
  • Neurocrine Biosciences' Cash & Current Investments stood at $714.5 million in 2021, then surged by 39.55% to $997.1 million in 2022, then increased by 4.26% to $1.0 billion in 2023, then increased by 3.51% to $1.1 billion in 2024, then skyrocketed by 37.57% to $1.5 billion in 2025.
  • The last three reported values for Cash & Current Investments were $1.5 billion (Q4 2025), $1.1 billion (Q3 2025), and $975.6 million (Q2 2025) per Business Quant data.